Suppression of the Ewing's sarcoma phenotype by FLI1/ERF repressor hybrids.

abstract：:Although early stage cholangiocarcinoma (CC) can be cured by surgical extirpation, the options for treatment of advanced stage CC are very few and suboptimal. Oncolytic virotherapy using replication-competent vaccinia virus (VACV) is a promising new strategy to treat human cancers. The ability of oncolytic VACV GLV-1h...

journal_title：Cancer gene therapy

authors： Pugalenthi A,Mojica K,Ady JW,Johnsen C,Love D,Chen NG,Aguilar RJ,Szalay AA,Fong Y

更新日期：2015-12-01 00:00:00

abstract：:A phase l study using intravesical Ad-IFNαSyn3 for patients with bacillus Calmette-Guérin-resistant superficial bladder cancer showed a complete remission (CR) of 43% at 90 days after treatment with high levels of interferon-α (IFNα) being produced. Ad-IFNα kills bladder cancer cells by two apoptotic and one necrotic ...

journal_title：Cancer gene therapy

authors： Benedict WF,Fisher M,Zhang XQ,Yang Z,Munsell MF,Dinney CN

更新日期：2014-03-01 00:00:00

abstract：:At the Eleventh International Conference on Gene Therapy of Cancer (December 12-14, 2002, San Diego, CA) progress on using gene transfer technology to treat cancer was presented. Although there is as yet no cancer gene therapy being marketed, considerable progress has been made in defining likely strategies and likely...

journal_title：Cancer gene therapy

authors： Gottesman MM

更新日期：2003-07-01 00:00:00

abstract：:Thymidylate synthase (TS) catalyzes de novo production of thymidylate for DNA synthesis and cell proliferation. As such, TS has been a target of antitumor chemotherapy for many years. Our laboratory has identified several antisense oligodeoxynucleotides (ODNs) that downregulate TS mRNA and protein, inhibit cell prolif...

journal_title：Cancer gene therapy

authors： Berg RW,Ferguson PJ,Vincent MD,Koropatnick DJ

更新日期：2003-04-01 00:00:00

abstract：:The zinc-fingers and homeoboxes (ZHX) family is a group of nuclear homodimeric transcriptional repressors that interact with a subunit of nuclear factor-Y (NF-YA) and contain two C2H2-type zinc fingers and five homeobox DNA-binding domains. The members of ZHX family form homodimers or heterodimers with other members o...

journal_title：Cancer gene therapy

authors： Liu Y,Ma D,Ji C

更新日期：2015-05-01 00:00:00

abstract：:It has been demonstrated that survivin, a novel member of the inhibitor of apoptosis (IAP) protein family, is expressed in human cancers but is undetectable in normal differentiated tissues. We employed a recombinant adenoviral vector (reAdGL3BSurvivin) in which a tumor-specific survivin promoter and a luciferase repo...

journal_title：Cancer gene therapy

authors： Zhu ZB,Makhija SK,Lu B,Wang M,Kaliberova L,Liu B,Rivera AA,Nettelbeck DM,Mahasreshti PJ,Leath CA,Barker S,Yamaoto M,Li F,Alvarez RD,Curiel DT

更新日期：2004-04-01 00:00:00

abstract：:Replication-competent oncolytic herpes simplex viruses (HSV), modified by deletion of certain viral growth genes, can selectively target malignant cells. The viral growth gene gamma(1)34.5 has significant homology to GADD34 (growth arrest and DNA damage protein 34), which promotes cell cycle arrest and DNA repair in r...

journal_title：Cancer gene therapy

authors： Jarnagin WR,Zager JS,Hezel M,Stanziale SF,Adusumilli PS,Gonen M,Ebright MI,Culliford A,Gusani NJ,Fong Y

更新日期：2006-03-01 00:00:00

abstract：:Transforming growth factor-beta (TGF-beta) is a potent immunosuppressive cytokine produced by many tumor cells. Secretion of TGF-beta by malignant cells may therefore be a mechanism by which tumor cells escape destruction by tumor-specific T lymphocytes. In order to evaluate the role of tumor-derived TGF-beta on tumor...

journal_title：Cancer gene therapy

authors： Park JA,Wang E,Kurt RA,Schluter SF,Hersh EM,Akporiaye ET

更新日期：1997-01-01 00:00:00

abstract：:The fact that glioblastomas, which are one of the most devastating cancers, frequently express the Delta-EGFR (epithelial growth factor receptor) also called mutant variant III of EGFR (EGFRvIII) suggests that this cancer cell-specific receptor might serve as an ideal target for cancer therapy. To assess its potential...

journal_title：Cancer gene therapy

authors： Piao Y,Jiang H,Alemany R,Krasnykh V,Marini FC,Xu J,Alonso MM,Conrad CA,Aldape KD,Gomez-Manzano C,Fueyo J

更新日期：2009-03-01 00:00:00

abstract：:Poor tumor targeting of oncolytic adenoviruses (OAdv) after systemic administration is considered a major limitation for virotherapy of disseminated cancers. The benefit of using mesenchymal stem cells as cell carriers for OAdv tumor targeting is currently evaluated not only in preclinical models but also in clinical ...

journal_title：Cancer gene therapy

authors： Barlabé P,Sostoa J,Fajardo CA,Alemany R,Moreno R

更新日期：2020-05-01 00:00:00

abstract：:The Holliday Junction-Recognition Protein (HJURP) was reported as overexpressed in several cancers and also strongly correlated with poor prognosis of patients, especially in glioblastoma (GBM), the most common and deadly type of primary brain tumor. HJURP is responsible for loading the histone H3 variant-the Centrome...

journal_title：Cancer gene therapy

authors： Serafim RB,Cardoso C,Di Cristofaro LFM,Pienna Soares C,Araújo Silva W Jr,Espreafico EM,Paçó-Larson ML,Price BD,Valente V

更新日期：2020-05-01 00:00:00

abstract：:Herpes simplex viruses (HSVs) are important pathogens and ideal for gene therapy due to its large genome size. Previous researches on HSVs were hampered because the technology to construct recombinant HSVs were based on DNA homology-dependent repair (HDR) and plaque assay, which are inefficient, laborious, and time-co...

journal_title：Cancer gene therapy

authors： Wang D,Wang XW,Peng XC,Xiang Y,Song SB,Wang YY,Chen L,Xin VW,Lyu YN,Ji J,Ma ZW,Li CB,Xin HW

更新日期：2018-06-01 00:00:00

abstract：:Oncolytic adenoviruses are promising anticancer agents. To study and optimize their tumor-killing potency, genuine tumor models are required. Here we describe the use of the chicken chorioallantoic membrane (CAM) tumor model in studies on oncolytic adenoviral vectors. Suspensions of human melanoma, colorectal carcinom...

journal_title：Cancer gene therapy

authors： Durupt F,Koppers-Lalic D,Balme B,Budel L,Terrier O,Lina B,Thomas L,Hoeben RC,Rosa-Calatrava M

更新日期：2012-01-01 00:00:00

abstract：:Immune checkpoint inhibition (ICI) has revolutionized cancer treatment, and produced durable responses in many cancer types. However, there remains a subset of patients that do not respond despite their tumors exhibiting PD-L1 expression, which highlights the need for additional biomarkers relevant to response. Here, ...

journal_title：Cancer gene therapy

authors： Choucair K,Morand S,Stanbery L,Edelman G,Dworkin L,Nemunaitis J

更新日期：2020-12-01 00:00:00

abstract：:Immune responses to tumor-associated antigens are often dampened by a tumor-induced state of immune anergy. Previous work has attempted to overcome tumor-induced T-cell anergy by the direct injection of vectors carrying the genes encoding one of a variety of cytokines. We hypothesised that the polyclonal stimulation o...

journal_title：Cancer gene therapy

authors： Paul S,Regulier E,Rooke R,Stoeckel F,Geist M,Homann H,Balloul JM,Villeval D,Poitevin Y,Kieny MP,Acres RB

更新日期：2002-05-01 00:00:00

abstract：:Cancer gene therapy approaches are often designed as single-agent treatments; however, greater therapeutic effect might be obtained if combined with an established conventional treatment regimen such as chemotherapy. In this context, conditional promoters are useful tools, because they may be induced by therapeutic mo...

journal_title：Cancer gene therapy

authors： Walther W,Stein U,Fichtner I,Alexander M,Shoemaker RH,Schlag PM

更新日期：2000-06-01 00:00:00

abstract：:ING4 as a member of inhibitor of growth (ING) tumor suppressor family has potent inhibitory effects on a variety of tumors. Interleukin-24 (IL-24), a cytokine-tumor suppressor, also shows broad-spectrum and tumor-specific antitumor activities. In this report, we constructed an ING4/IL-24 bicistronic adenovirus (Ad-ING...

journal_title：Cancer gene therapy

authors： Zhu Y,Lv H,Xie Y,Sheng W,Xiang J,Yang J

更新日期：2011-09-01 00:00:00

abstract：:A novel gene, HA117, was discovered in our previous work. Using the pSOS-HUS vector method which we designed at previous study, we screened for small interfering RNAs (siRNAs) that targeted HA117. The pSOS-HUS siRNA screening results were verified and a delivery system was developed that contained a recombinant adenov...

journal_title：Cancer gene therapy

authors： Zheng GH,Luo Q,Jin XQ,Guo YX,Xu YH

更新日期：2011-09-01 00:00:00

abstract：:RNA interference (RNAi) is a natural cellular regulatory process that inhibits gene expression by transcriptional, post-transcriptional and translational mechanisms. Synthetic approaches that emulate this process (small interfering RNA (siRNA), short hairpin RNA (shRNA)) have been shown to be similarly effective in th...

journal_title：Cancer gene therapy

authors： Rao DD,Maples PB,Senzer N,Kumar P,Wang Z,Pappen BO,Yu Y,Haddock C,Jay C,Phadke AP,Chen S,Kuhn J,Dylewski D,Scott S,Monsma D,Webb C,Tong A,Shanahan D,Nemunaitis J

更新日期：2010-11-01 00:00:00

abstract：:Using our model to grow superficial human bladder cancer in the mouse bladder, we have found that the polyamide compound, Syn3, when injected intravesically for 1 hour at 1 mg/mL on two consecutive days, markedly increases rAd-beta-gal intravesical gene transfer and expression. This enhanced transgene expression was m...

journal_title：Cancer gene therapy

authors： Yamashita M,Rosser CJ,Zhou JH,Zhang XQ,Connor RJ,Engler H,Maneval DC,Karashima T,Czerniak BA,Dinney CP,Benedict WF

更新日期：2002-08-01 00:00:00

abstract：:Hepatocellular carcinoma (HCC) recurrence is one of the leading causes of death after orthotopic liver transplantation (OLT). The sixth complement component (C6) is a late-acting complement protein that participates in the assembly of the membrane attack complex, which has an indispensable role in innate and acquired ...

journal_title：Cancer gene therapy

authors： Wang Z,Liao J,Wu S,Li C,Fan J,Peng Z

更新日期：2016-06-01 00:00:00

abstract：:In this article we describe an improved method to produce a conjugate of anti-erythrocyte growth factor (EGF) receptor monoclonal antibody with polylysine via thio-ether bonds. The resulting antibody/polylysine conjugate was found to be a much more stable DNA (gene) carrier than the previous conjugate formed via disul...

journal_title：Cancer gene therapy

authors： Shimizu N,Chen J,Gamou S,Takayanagi A

更新日期：1996-03-01 00:00:00

abstract：:Metastasis is the principal cause of cancer death and occurs through multiple, complex processes. Epithelial to mesenchymal transition (EMT) is an important process during embryonic development and has also been hypothesized to exhibit a significant role in cancer cell invasion and metastasis. MicroRNAs (miRNAs) are a...

journal_title：Cancer gene therapy

authors： Zhang Z,Zhang M,Chen Q,Zhang Q

更新日期：2017-02-01 00:00:00

abstract：:The p16INK4 tumor suppressor gene encodes a protein that inhibits cyclin-dependent kinase 4, and its homologous deletion is common in human breast cancer. p16INK4 gene transfer has been reported to be efficacious in inducing growth inhibition of various human tumors such as brain, lung, prostate, and esophageal cancer...

journal_title：Cancer gene therapy

authors： Campbell I,Magliocco A,Moyana T,Zheng C,Xiang J

更新日期：2000-09-01 00:00:00

abstract：:The present study was designed to investigate the upstream transcription factors (TFs) and the signature genes in cholangiocarcinoma (CCA), providing better clues on the regulatory mechanisms and therapeutic applications. Gene expression data sets of CCA were searched in the Gene Expression Omnibus database for integr...

journal_title：Cancer gene therapy

authors： Yang L,Feng S,Yang Y

更新日期：2016-12-01 00:00:00

abstract：:Most advanced solid tumors metastasize to different organs. However, no gene therapy effective for multiple tumors has yet been developed. Since a unique characteristic of bone marrow-derived mesenchymal stem cells (MSCs) is that they migrate to tumor tissues, we wanted to determine whether MSCs could serve as a vehic...

journal_title：Cancer gene therapy

authors： Kanehira M,Xin H,Hoshino K,Maemondo M,Mizuguchi H,Hayakawa T,Matsumoto K,Nakamura T,Nukiwa T,Saijo Y

更新日期：2007-11-01 00:00:00

abstract：:The use of genetically modified tumor cells as vaccines has been successful in numerous animal models of grafted syngenic tumors and has provided the groundwork for many clinical trials of gene therapy in cancer patients. To investigate the real efficacy of ex vivo gene therapy-based vaccines, we used transgenic mice ...

journal_title：Cancer gene therapy

authors： Morel A,de La Coste A,Fernandez N,Berson A,Kaybanda M,Molina T,Briand P,Haddada H,Guillet JG,Antoine B,Viguier M,Kahn A

更新日期：1998-03-01 00:00:00

abstract：:This study was performed with the aim to investigate the correlations of tumor necrosis factor-alpha (TNF-α) gene promoter polymorphisms with the risk of thymoma-associated myasthenia gravis (T-MG) in a northern Chinese Han population. Between June 2005 and June 2015, 305 MG patients (150 males and 155 females, MG gro...

journal_title：Cancer gene therapy

authors： Yang HW,Lei P,Xie YC,Han ZL,Li D,Wang SH,Sun ZL

更新日期：2017-06-01 00:00:00

abstract：:The human epidermal growth factor receptors 2, 3, and 4 (HER2, HER3, and HER4, respectively) are frequently overexpressed in many human cancers, and therefore may be potential targets for receptor-mediated gene transfer. To evaluate this possibility, we constructed a series of HER-targeted gene transfer vehicles by co...

journal_title：Cancer gene therapy

authors： Kern JA,Wakita R,Sliwkowski MX

更新日期：1999-11-01 00:00:00

abstract：:Aberrantly expressed microRNAs (miRNAs) are involved in breast tumorigenesis. It is still unclear if and how miRNAs-221/222 are implicated in breast cancer and the resistance to estrogen receptor modulator tamoxifen. We investigated the roles and mechanisms of miR-221/222 in breast cancer cells, particularly in modula...

journal_title：Cancer gene therapy

authors： Gan R,Yang Y,Yang X,Zhao L,Lu J,Meng QH

更新日期：2014-07-01 00:00:00